In 2017, it’s projected that a variety of new treatments will enter the clinical trials space. However, not all of these trials will be well suited to the capabilities of your research site. Successful sites must distinguish between studies that will contribute to their long-term growth and studies that should be declined.
In this webinar, you’ll learn:
About the Presenters:
Doug is an Associate Director of Clinical Operations at ClinEdge. He works with both sites and sponsors/CROs in a variety of capacities to optimize and streamline the site selection process. Doug and his team provide personalized business development to a network of elite research sites and are constantly finding new ways to make site processes operationally efficient. He holds a bachelor’s degree in English from Tufts University.
Tami is the Product Marketing Manager for Overture EDC at Forte. Overture is a user-friendly electronic data capture system with an elegant design and easy-to-navigate user interface, that fully supports compliance with 21 CFR Part 11.